Hans-Peter Kiem

List of Publications by Citations

298 papers	12,537 citations	56 h-index	106 g-index
325 ext. papers	14,453 ext. citations	6.3 avg, IF	5.8 L-index

#	Paper	IF	Citations
298	SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues. *Cell*, **2020**, 181, 1016-1035.e19	56.2	1326
297	Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. *Blood*, **2001**, 97, 3390-400	2.2	1183
296	Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. *Nature* , **2014**, 510, 273-7	50.4	939
295	Stable Mixed Hematopoietic Chimerism in DLA-Identical Littermate Dogs Given Sublethal Total Body Irradiation Before and Pharmacological Immunosuppression After Marrow Transplantation. *Blood*, **1997**, 89, 3048-3054	2.2	536
294	Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. *Blood*, **2011**, 117, 3214-9	2.2	420
293	Cord blood expansion. Pyrimidoindole derivatives are agonists of human hematopoietic stem cell self-renewal. *Science*, **2014**, 345, 1509-12	33.3	339
292	International AIDS Society global scientific strategy: towards an HIV cure 2016. *Nature Medicine*, **2016**, 22, 839-50	50.5	303
291	Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. *Blood*, **2002**, 100, 1201-7	2.2	253
290	Allogeneic hematopoietic stem cell transplantation for myelofibrosis. *Blood*, **2003**, 102, 3912-8	2.2	228
289	Foamy virus vector integration sites in normal human cells. *Proceedings of the National Academy of Sciences of the United States of America*, **2006**, 103, 1498-503	11.5	214
288	Polyclonal long-term repopulating stem cell clones in a primate model. *Blood*, **2002**, 100, 2737-43	2.2	204
287	Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. *Blood*, **2019**, 133, 1652-1663	2.2	158
286	American Society of Gene Therapy (ASGT) ad hoc subcommittee on retroviral-mediated gene transfer to hematopoietic stem cells. *Molecular Therapy*, **2003**, 8, 180-7	11.7	129
285	The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. *Blood*, **2019**, 133, 1876-1887	2.2	126
284	Comparison of mesenchymal stem cells from different tissues to suppress T-cell activation. *Cell Transplantation*, **2007**, 16, 555-62	4	118
283	A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. *Biology of Blood and Marrow Transplantation*, **2005**, 11, 495-505	4.7	108
282	Comparison of HIV-derived lentiviral and MLV-based gammaretroviral vector integration sites in primate repopulating cells. *Molecular Therapy*, **2007**, 15, 1356-65	11.7	96

281	Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. *Journal of Clinical Investigation*, **2003**, 112, 1581-1588	15.9	92
280	Hematopoietic-stem-cell-based gene therapy for HIV disease. *Cell Stem Cell*, **2012**, 10, 137-47	18	91
279	Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. *Journal of Immunology*, **2002**, 169, 2164-71	5.3	91
278	High incidence of leukemia in large animals after stem cell gene therapy with a HOXB4-expressing retroviral vector. *Journal of Clinical Investigation*, **2008**, 118, 1502-10	15.9	91
277	Polyclonal chemoprotection against temozolomide in a large-animal model of drug resistance gene therapy. *Blood*, **2005**, 105, 997-1002	2.2	89
276	Highly efficient gene transfer into baboon marrow repopulating cells using GALV-pseudotype oncoretroviral vectors produced by human packaging cells. *Blood*, **2002**, 100, 3960-7	2.2	88
275	Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates. *Journal of Clinical Investigation*, **2010**, 120, 2345-54	15.9	86
274	Long-term clinical and molecular follow-up of large animals receiving retrovirally transduced stem and progenitor cells: no progression to clonal hematopoiesis or leukemia. *Molecular Therapy*, **2004**, 9, 389-95	11.7	86
273	Extended core sequences from the cHS4 insulator are necessary for protecting retroviral vectors from silencing position effects. *Human Gene Therapy*, **2007**, 18, 333-43	4.8	84
272	Vascular niche promotes hematopoietic multipotent progenitor formation from pluripotent stem cells. *Journal of Clinical Investigation*, **2015**, 125, 1243-54	15.9	80
271	Extended survival of glioblastoma patients after chemoprotective HSC gene therapy. *Science Translational Medicine*, **2012**, 4, 133ra57	17.5	77
270	Interleukin-7 improves CD4 T-cell reconstitution after autologous CD34 cell transplantation in monkeys. *Blood*, **2003**, 101, 4209-18	2.2	77
269	Gene therapy enhances chemotherapy tolerance and efficacy in glioblastoma patients. *Journal of Clinical Investigation*, **2014**, 124, 4082-92	15.9	77
268	Evaluation of biodistribution and safety of adenovirus vectors containing group B fibers after intravenous injection into baboons. *Human Gene Therapy*, **2005**, 16, 664-77	4.8	76
267	Reduced incidence of acute and chronic graft-versus-host disease with the addition of thymoglobulin to a targeted busulfan/cyclophosphamide regimen. *Biology of Blood and Marrow Transplantation*, **2006**, 12, 573-84	4.7	75
266	Coupling endonucleases with DNA end-processing enzymes to drive gene disruption. *Nature Methods*, **2012**, 9, 973-5	21.6	72
265	Continuous electrical oscillations emerge from a coupled network: a study of the inferior olive using lentiviral knockdown of connexin36. *Journal of Neuroscience*, **2006**, 26, 5008-16	6.6	71
264	Morbidity and mortality of chronic GVHD after hematopoietic stem cell transplantation from HLA-identical siblings for patients with aplastic or refractory anemias. *Biology of Blood and Marrow Transplantation*, **2002**, 8, 47-56	4.7	71

263	Positive selection of mC46-expressing CD4+ T cells and maintenance of virus specific immunity in a primate AIDS model. *Blood*, **2013**, 122, 179-87	2.2	70
262	Sustained multilineage gene persistence and expression in dogs transplanted with CD34(+) marrow cells transduced by RD114-pseudotype oncoretrovirus vectors. *Blood*, **2001**, 98, 2065-70	2.2	70
261	Efficient lentiviral gene transfer to canine repopulating cells using an overnight transduction protocol. *Blood*, **2004**, 103, 3710-6	2.2	69
260	Pharmacologically regulated in vivo selection in a large animal. *Blood*, **2002**, 100, 2026-31	2.2	69
259	Rapamycin relieves lentiviral vector transduction resistance in human and mouse hematopoietic stem cells. *Blood*, **2014**, 124, 913-23	2.2	68
258	Unique integration profiles in a canine model of long-term repopulating cells transduced with gammaretrovirus, lentivirus, or foamy virus. *Human Gene Therapy*, **2007**, 18, 423-34	4.8	68
257	Targeted homology-directed repair in blood stem and progenitor cells with CRISPR nanoformulations. *Nature Materials*, **2019**, 18, 1124-1132	27	67
256	Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. *Nature Communications*, **2020**, 11, 219	17.4	67
255	Hematopoietic stem-cell behavior in nonhuman primates. *Blood*, **2007**, 110, 1806-13	2.2	65
254	Fundamental role of inferior olive connexin 36 in muscle coherence during tremor. *Proceedings of the National Academy of Sciences of the United States of America*, **2004**, 101, 7164-9	11.5	64
253	HLA-matched related donor hematopoietic cell transplantation in 43 patients with Fanconi anemia conditioned with 60 mg/kg of cyclophosphamide. *Biology of Blood and Marrow Transplantation*, **2007**, 13, 1455-60	4.7	63
252	Distinct hematopoietic stem/progenitor cell populations are responsible for repopulating NOD/SCID mice compared with nonhuman primates. *Blood*, **2003**, 102, 4329-35	2.2	63
251	Efficient transduction of pigtailed macaque hematopoietic repopulating cells with HIV-based lentiviral vectors. *Blood*, **2008**, 111, 5537-43	2.2	61
250	Therapeutically relevant engraftment of a CRISPR-Cas9-edited HSC-enriched population with HbF reactivation in nonhuman primates. *Science Translational Medicine*, **2019**, 11,	17.5	59
249	A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models. *Cancer Research*, **2007**, 67, 8783-90	10.1	59
248	Survival of the fittest: in vivo selection and stem cell gene therapy. *Blood*, **2006**, 107, 1751-60	2.2	59
247	Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. *Biology of Blood and Marrow Transplantation*, **2002**, 8, 206-12	4.7	59
246	In vivo transduction of primitive mobilized hematopoietic stem cells after intravenous injection of integrating adenovirus vectors. *Blood*, **2016**, 128, 2206-2217	2.2	59

245	A distinct hematopoietic stem cell population for rapid multilineage engraftment in nonhuman primates. *Science Translational Medicine*, **2017**, 9,	17.5	57
244	Induction of cytotoxic T-lymphocyte responses to enhanced green and yellow fluorescent proteins after myeloablative conditioning. *Blood*, **2004**, 103, 492-9	2.2	57
243	Efficient transduction by an amphotropic retrovirus vector is dependent on high-level expression of the cell surface virus receptor. *Journal of Virology*, **1999**, 73, 495-500	6.6	57
242	Foamy-virus-mediated gene transfer to canine repopulating cells. *Blood*, **2007**, 109, 65-70	2.2	55
241	Nonmyeloablative Hematopoietic Cell Transplantation. *Annals of the New York Academy of Sciences*, **2006**, 938, 328-339	6.5	55
240	Long-term persistence and function of hematopoietic stem cell-derived chimeric antigen receptor T cells in a nonhuman primate model of HIV/AIDS. *PLoS Pathogens*, **2017**, 13, e1006753	7.6	54
239	Protection of stem cell-derived lymphocytes in a primate AIDS gene therapy model after in vivo selection. *PLoS ONE*, **2009**, 4, e7693	3.7	52
238	Nonmyeloablative immunosuppressive regimen prolongs In vivo persistence of gene-modified autologous T cells in a nonhuman primate model. *Journal of Virology*, **2001**, 75, 799-808	6.6	52
237	Concurrent blockade of alpha4-integrin and CXCR4 in hematopoietic stem/progenitor cell mobilization. *Stem Cells*, **2009**, 27, 836-7	5.8	51
236	Long-term multilineage engraftment of autologous genome-edited hematopoietic stem cells in nonhuman primates. *Blood*, **2016**, 127, 2416-26	2.2	50
235	Safeguarding nonhuman primate iPS cells with suicide genes. *Molecular Therapy*, **2011**, 19, 1667-75	11.7	46
234	Targeted gene disruption to cure HIV. *Current Opinion in HIV and AIDS*, **2013**, 8, 217-23	4.2	44
233	Differential effects of HOXB4 on nonhuman primate short- and long-term repopulating cells. *PLoS Medicine*, **2006**, 3, e173	11.6	44
232	Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. *Biology of Blood and Marrow Transplantation*, **2008**, 14, 531-7	4.7	42
231	Chimeric antigen receptor T-cell approaches to HIV cure. *Current Opinion in HIV and AIDS*, **2018**, 13, 446-453	4.2	40
230	Severe canine hereditary hemolytic anemia treated by nonmyeloablative marrow transplantation. *Biology of Blood and Marrow Transplantation*, **2001**, 7, 14-24	4.7	40
229	Multilineage polyclonal engraftment of Cal-1 gene-modified cells and in vivo selection after SHIV infection in a nonhuman primate model of AIDS. *Molecular Therapy - Methods and Clinical Development*, **2016**, 3, 16007	6.4	39
228	Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. *Blood*, **2021**, 137, 323-335	2.2	39

227	Treatment change as a predictor of outcome among patients with classic chronic graft-versus-host disease. *Biology of Blood and Marrow Transplantation*, **2008**, 14, 1380-4	4.7	38
226	Cocal-pseudotyped lentiviral vectors resist inactivation by human serum and efficiently transduce primate hematopoietic repopulating cells. *Molecular Therapy*, **2010**, 18, 725-33	11.7	37
225	Outcome of allogeneic hematopoietic cell transplantation from HLA-identical siblings for severe aplastic anemia in patients over 40 years of age. *Biology of Blood and Marrow Transplantation*, **2010**, 16, 1411-8	4.7	37
224	Methylguanine methyltransferase-mediated in vivo selection and chemoprotection of allogeneic stem cells in a large-animal model. *Journal of Clinical Investigation*, **2003**, 112, 1581-8	15.9	36
223	Long-term persistence of canine hematopoietic cells genetically marked by retrovirus vectors. *Human Gene Therapy*, **1996**, 7, 89-96	4.8	35
222	Efficient gene transfer to hematopoietic repopulating cells using concentrated RD114-pseudotype vectors produced by human packaging cells. *Molecular Therapy*, **2004**, 9, 157-9	11.7	34
221	Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Children and Adolescents with Fanconi Anemia. *Biology of Blood and Marrow Transplantation*, **2017**, 23, 310-317	4.7	33
220	Stem cell gene therapy for fanconi anemia: report from the 1st international Fanconi anemia gene therapy working group meeting. *Molecular Therapy*, **2011**, 19, 1193-8	11.7	33
219	TALEN-Mediated Gene Editing of in Human Hematopoietic Stem Cells Leads to Therapeutic Fetal Hemoglobin Induction. *Molecular Therapy - Methods and Clinical Development*, **2019**, 12, 175-183	6.4	31
218	VISA--Vector Integration Site Analysis server: a web-based server to rapidly identify retroviral integration sites from next-generation sequencing. *BMC Bioinformatics*, **2015**, 16, 212	3.6	31
217	Scaffold attachment region-containing retrovirus vectors improve long-term proviral expression after transplantation of GFP-modified CD34+ baboon repopulating cells. *Blood*, **2003**, 102, 3117-9	2.2	31
216	Intravenous injection of a foamy virus vector to correct canine SCID-X1. *Blood*, **2014**, 123, 3578-84	2.2	30
215	A retrospective comparison of tacrolimus versus cyclosporine with methotrexate for immunosuppression after allogeneic hematopoietic cell transplantation with mobilized blood cells. *Biology of Blood and Marrow Transplantation*, **2011**, 17, 1088-92	4.7	30
214	Current and future preparative regimens for bone marrow transplantation in thalassemia. *Annals of the New York Academy of Sciences*, **1998**, 850, 276-87	6.5	30
213	Efficient generation, purification, and expansion of CD34(+) hematopoietic progenitor cells from nonhuman primate-induced pluripotent stem cells. *Blood*, **2012**, 120, e35-44	2.2	29
212	Combination of HOXB4 and Delta-1 ligand improves expansion of cord blood cells. *Blood*, **2010**, 116, 5859-66	2.2	29
211	Hematopoietic stem cell transduction and amplification in large animal models. *Human Gene Therapy*, **2005**, 16, 1355-66	4.8	29
210	A Nonhuman Primate Transplantation Model to Evaluate Hematopoietic Stem Cell Gene Editing Strategies for β-Hemoglobinopathies. *Molecular Therapy - Methods and Clinical Development*, **2018**, 8, 75-86	6.4	28

209	CCR5-edited gene therapies for HIV cure: Closing the door to viral entry. *Cytotherapy*, **2017**, 19, 1325-1338	4.8	28
208	Interleukin-7 improves reconstitution of antiviral CD4 T cells. *Clinical Immunology*, **2005**, 114, 30-41	9	28
207	High-throughput genomic mapping of vector integration sites in gene therapy studies. *Methods in Molecular Biology*, **2014**, 1185, 321-44	1.4	28
206	A Cure for HIV Infection: "Not in My Lifetime" or "Just Around the Corner"?. *Pathogens and Immunity*, **2016**, 1, 154-164	4.9	28
205	Effects of HOXB4 overexpression on ex vivo expansion and immortalization of hematopoietic cells from different species. *Stem Cells*, **2007**, 25, 2074-81	5.8	27
204	In vivo selection and chemoprotection after drug resistance gene therapy in a nonmyeloablative allogeneic transplantation setting in dogs. *Human Gene Therapy*, **2007**, 18, 451-6	4.8	27
203	Nanoparticle Biokinetics in Mice and Nonhuman Primates. *ACS Nano*, **2017**, 11, 9514-9524	16.7	26
202	Semi-automated closed system manufacturing of lentivirus gene-modified haematopoietic stem cells for gene therapy. *Nature Communications*, **2016**, 7, 13173	17.4	25
201	Endothelial Cells Promote Expansion of Long-Term Engrafting Marrow Hematopoietic Stem and Progenitor Cells in Primates. *Stem Cells Translational Medicine*, **2017**, 6, 864-876	6.9	25
200	Long-term polyclonal and multilineage engraftment of methylguanine methyltransferase P140K gene-modified dog hematopoietic cells in primary and secondary recipients. *Blood*, **2009**, 113, 5094-103	2.2	25
199	Human hematopoietic stem cell maintenance and myeloid cell development in next-generation humanized mouse models. *Blood Advances*, **2019**, 3, 268-274	7.8	25
198	Safety and Efficacy of Combination Antiretroviral Therapy in Human Immunodeficiency Virus-Infected Adults Undergoing Autologous or Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies. *Biology of Blood and Marrow Transplantation*, **2016**, 22, 149-56	4.7	24
197	Stem cell gene transfer--efficacy and safety in large animal studies. *Molecular Therapy*, **2004**, 10, 417-31	11.7	24
196	Efficient serum-free retroviral gene transfer into primitive human hematopoietic progenitor cells by a defined, high-titer, nonconcentrated vector-containing medium. *Human Gene Therapy*, **1998**, 9, 771-8	4.8	24
195	Lessons Learned from Two Decades of Clinical Trial Experience in Gene Therapy for Fanconi Anemia. *Current Gene Therapy*, **2017**, 16, 338-348	4.3	24
194	Engineering resistance to CD33-targeted immunotherapy in normal hematopoiesis by CRISPR/Cas9-deletion of CD33 exon 2. *Leukemia*, **2019**, 33, 762-808	10.7	24
193	Differential impact of transplantation on peripheral and tissue-associated viral reservoirs: Implications for HIV gene therapy. *PLoS Pathogens*, **2018**, 14, e1006956	7.6	23
192	A Combined HSC Transduction/Selection Approach Results in Efficient and Stable Gene Expression in Peripheral Blood Cells in Mice. *Molecular Therapy - Methods and Clinical Development*, **2018**, 8, 52-64	6.4	23

191	Efficient gene transfer in primitive CD34+/CD38lo human bone marrow cells reselected after long-term exposure to GALV-pseudotyped retroviral vector. *Human Gene Therapy*, **1997**, 8, 2079-86	4.8	22
190	The majority of CD4+ T-cell depletion during acute simian-human immunodeficiency virus SHIV89.6P infection occurs in uninfected cells. *Journal of Virology*, **2014**, 88, 3202-12	6.6	21
189	Toward a stem cell gene therapy for breast cancer. *Blood*, **2009**, 113, 5423-33	2.2	21
188	Suppression of luteinizing hormone enhances HSC recovery after hematopoietic injury. *Nature Medicine*, **2018**, 24, 239-246	50.5	20
187	Lentivirus-mediated Gene Transfer in Hematopoietic Stem Cells Is Impaired in SHIV-infected, ART-treated Nonhuman Primates. *Molecular Therapy*, **2015**, 23, 943-951	11.7	20
186	Hematopoietic stem cell expansion and gene therapy. *Cytotherapy*, **2011**, 13, 1164-71	4.8	20
185	Foamy and lentiviral vectors transduce canine long-term repopulating cells at similar efficiency. *Human Gene Therapy*, **2009**, 20, 519-23	4.8	20
184	Efficient characterization of retro-, lenti-, and foamyvector-transduced cell populations by high-accuracy insertion site sequencing. *Annals of the New York Academy of Sciences*, **2003**, 996, 112-21	6.5	20
183	Gene transfer into baboon repopulating cells: A comparison of Flt-3 Ligand and megakaryocyte growth and development factor versus IL-3 during ex vivo transduction. *Molecular Therapy*, **2001**, 3, 920-7	11.7	20
182	Differential engraftment of genetically modified CD34(+) and CD34(-) hematopoietic cell subsets in lethally irradiated baboons. *Experimental Hematology*, **2000**, 28, 508-18	3.1	20
181	Rapid immune reconstitution of SCID-X1 canines after G-CSF/AMD3100 mobilization and in vivo gene therapy. *Blood Advances*, **2018**, 2, 987-999	7.8	20
180	In Vivo Hematopoietic Stem Cell Transduction. *Hematology/Oncology Clinics of North America*, **2017**, 31, 771-785	3.1	19
179	Hematopoietic stem cell expansion facilitates multilineage engraftment in a nonhuman primate cord blood transplantation model. *Experimental Hematology*, **2012**, 40, 187-96	3.1	19
178	Direct comparison of steady-state marrow, primed marrow, and mobilized peripheral blood for transduction of hematopoietic stem cells in dogs. *Human Gene Therapy*, **2003**, 14, 1683-6	4.8	19
177	Development of Third-generation Cocal Envelope Producer Cell Lines for Robust Lentiviral Gene Transfer into Hematopoietic Stem Cells and T-cells. *Molecular Therapy*, **2016**, 24, 1237-46	11.7	19
176	Genetically modified hematopoietic stem cell transplantation for HIV-1-infected patients: can we achieve a cure?. *Molecular Therapy*, **2014**, 22, 257-264	11.7	18
175	Efficient marking of murine long-term repopulating stem cells targeting unseparated marrow cells at low lentiviral vector particle concentration. *Molecular Therapy*, **2004**, 9, 914-22	11.7	18
174	Kinetics of fluorescence expression in nonhuman primates transplanted with GFP retrovirus-modified CD34 cells. *Molecular Therapy*, **2002**, 6, 83-90	11.7	18

173	HLA-Haploidentical Hematopoietic Cell Transplantation for Treatment of Nonmalignant Diseases Using Nonmyeloablative Conditioning and Post-Transplant Cyclophosphamide. *Biology of Blood and Marrow Transplantation*, **2020**, 26, 1332-1341	4.7	17
172	Loss of immune homeostasis dictates SHIV rebound after stem-cell transplantation. *JCI Insight*, **2017**, 2, e91230	9.9	17
171	Lessons from London and Berlin: Designing A Scalable Gene Therapy Approach for HIV Cure. *Cell Stem Cell*, **2019**, 24, 685-687	18	16
170	Resveratrol trimer enhances gene delivery to hematopoietic stem cells by reducing antiviral restriction at endosomes. *Blood*, **2019**, 134, 1298-1311	2.2	16
169	Simian varicella virus in pigtailed macaques (Macaca nemestrina): clinical, pathologic, and virologic features. *Comparative Medicine*, **2009**, 59, 482-7	1.6	16
168	Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021. *Nature Medicine*, **2021**,	50.5	16
167	Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates. *Blood*, **2020**, 136, 1722-1734	2.2	15
166	Cell and Gene Therapy for HIV Cure. *Current Topics in Microbiology and Immunology*, **2018**, 417, 211-248	3.3	15
165	Differential responses of FLIPLong and FLIPShort-overexpressing human myeloid leukemia cells to TNF-alpha and TRAIL-initiated apoptotic signals. *Experimental Hematology*, **2008**, 36, 1660-72	3.1	15
164	Longitudinal assessment of morbidity and acute graft-versus-host disease after allogeneic hematopoietic cell transplantation: retrospective analysis of a multicenter phase III study. *Biology of Blood and Marrow Transplantation*, **2009**, 15, 749-56	4.7	14
163	Differential effects of bexarotene on intrinsic and extrinsic pathways in TRAIL-induced apoptosis in two myeloid leukemia cell lines. *Leukemia and Lymphoma*, **2007**, 48, 1003-14	1.9	14
162	Efficient transduction and engraftment of G-CSF-mobilized peripheral blood CD34+ cells in nonhuman primates using GALV-pseudotyped gammaretroviral vectors. *Molecular Therapy*, **2006**, 14, 212-7	11.7	14
161	Gene transfer into fetal baboon hematopoietic progenitor cells. *Human Gene Therapy*, **1999**, 10, 667-77	4.8	14
160	HIV eradication--from Berlin to Boston. *Nature Biotechnology*, **2014**, 32, 315-6	44.5	13
159	Robust suppression of env-SHIV viremia in Macaca nemestrina by 3-drug ART is independent of timing of initiation during chronic infection. *Journal of Medical Primatology*, **2013**, 42, 237-46	0.7	13
158	Long-term regulation of genetically modified primary hematopoietic cells in dogs. *Molecular Therapy*, **2011**, 19, 1287-94	11.7	13
157	De novo generation of CD4 T cells against viruses present in the host during immune reconstitution. *Blood*, **2005**, 105, 2410-4	2.2	13
156	Purification of Human CD34CD90 HSCs Reduces Target Cell Population and Improves Lentiviral Transduction for Gene Therapy. *Molecular Therapy - Methods and Clinical Development*, **2020**, 18, 679-691	6.4	13

155	Long-Term Persistence of Anti-HIV Broadly Neutralizing Antibody-Secreting Hematopoietic Cells in Humanized Mice. *Molecular Therapy*, **2019**, 27, 164-177	11.7	13
154	Autologous Stem Cell Transplantation Disrupts Adaptive Immune Responses during Rebound Simian/Human Immunodeficiency Virus Viremia. *Journal of Virology*, **2017**, 91,	6.6	12
153	Hematopoietic Stem Cell Approaches to Cancer. *Hematology/Oncology Clinics of North America*, **2017**, 31, 897-912	3.1	12
152	Lack of viral control and development of combination antiretroviral therapy escape mutations in macaques after bone marrow transplantation. *Aids*, **2015**, 29, 1597-606	3.5	12
151	Stable marking and transgene expression without progression to monoclonality in canine long-term hematopoietic repopulating cells transduced with lentiviral vectors. *Human Gene Therapy*, **2010**, 21, 397-403	4.8	12
150	GaLV pseudotyped vectors and cationic lipids transduce human CD34+ cells. *Human Gene Therapy*, **1997**, 8, 1685-94	4.8	12
149	Tightly regulated gene expression in human hematopoietic stem cells after transduction with helper-dependent Ad5/35 vectors. *Experimental Hematology*, **2008**, 36, 823-31	3.1	12
148	Immuno-therapy with anti-CTLA4 antibodies in tolerized and non-tolerized mouse tumor models. *PLoS ONE*, **2011**, 6, e22303	3.7	12
147	Effective Multi-lineage Engraftment in a Mouse Model of Fanconi Anemia Using Non-genotoxic Antibody-Based Conditioning. *Molecular Therapy - Methods and Clinical Development*, **2020**, 17, 455-464	6.4	12
146	In Vivo Murine-Matured Human CD3 Cells as a Preclinical Model for T Cell-Based Immunotherapies. *Molecular Therapy - Methods and Clinical Development*, **2017**, 6, 17-30	6.4	11
145	(211)Astatine-Conjugated Monoclonal CD45 Antibody-Based Nonmyeloablative Conditioning for Stem Cell Gene Therapy. *Human Gene Therapy*, **2015**, 26, 399-406	4.8	11
144	Large animal models for foamy virus vector gene therapy. *Viruses*, **2012**, 4, 3572-88	6.2	11
143	Differences in F36VMpl-based in vivo selection among large animal models. *Molecular Therapy*, **2004**, 10, 730-40	11.7	11
142	Engraftment of DLA-haploidentical marrow with ex vivo expanded, retrovirally transduced cytotoxic T lymphocytes. *Blood*, **2001**, 98, 3447-55	2.2	11
141	Ex vivo selection for oncoretrovirally transduced green fluorescent protein-expressing CD34-enriched cells increases short-term engraftment of transduced cells in baboons. *Human Gene Therapy*, **2002**, 13, 891-9	4.8	11
140	Charting a clear path: the ASGCT Standardized Pathways Conference. *Molecular Therapy*, **2014**, 22, 1235-1238	11.7	10
139	Modeling promising nonmyeloablative conditioning regimens in nonhuman primates. *Human Gene Therapy*, **2014**, 25, 1013-22	4.8	10
138	Gene therapy in the transplantation of allogeneic organs and stem cells. *Current Gene Therapy*, **2007**, 7, 458-68	4.3	10

137	Reduced toxicity and prompt engraftment after minimal conditioning of a patient with Fanconi anemia undergoing hematopoietic stem cell transplantation from an HLA-matched unrelated donor. *Journal of Pediatric Hematology/Oncology*, **2003**, 25, 581-3	1.2	10
136	Canine T cells transduced with a herpes simplex virus thymidine kinase gene: a model to study effects on engraftment and control of graft-versus-host disease. *Transplantation*, **1998**, 66, 540-4	1.8	10
135	Safe and Effective Gene Therapy for Murine Wiskott-Aldrich Syndrome Using an Insulated Lentiviral Vector. *Molecular Therapy - Methods and Clinical Development*, **2017**, 4, 1-16	6.4	9
134	Pigtailed macaques as a model to study long-term safety of lentivirus vector-mediated gene therapy for hemoglobinopathies. *Molecular Therapy - Methods and Clinical Development*, **2014**, 1, 14055	6.4	9
133	Cyclophosphamide promotes engraftment of gene-modified cells in a mouse model of Fanconi anemia without causing cytogenetic abnormalities. *Journal of Molecular Medicine*, **2012**, 90, 1283-94	5.5	9
132	Genetic modification of hematopoietic stem cells as a therapy for HIV/AIDS. *Viruses*, **2013**, 5, 2946-62	6.2	9
131	Complications of a temozolomide overdose: a case report. *Journal of Neuro-Oncology*, **2006**, 80, 57-61	4.8	9
130	MISTRG mice support engraftment and assessment of nonhuman primate hematopoietic stem and progenitor cells. *Experimental Hematology*, **2019**, 70, 31-41.e1	3.1	9
129	Novel lineage depletion preserves autologous blood stem cells for gene therapy of Fanconi anemia complementation group A. *Haematologica*, **2018**, 103, 1806-1814	6.6	8
128	Current translational and clinical practices in hematopoietic cell and gene therapy. *Cytotherapy*, **2012**, 14, 775-90	4.8	8
127	CD34(+) expansion with Delta-1 and HOXB4 promotes rapid engraftment and transfusion independence in a Macaca nemestrina cord blood transplant model. *Molecular Therapy*, **2013**, 21, 1270-8	11.7	8
126	Transmission and expansion of HOXB4-induced leukemia in two immunosuppressed dogs: implications for a new canine leukemia model. *Experimental Hematology*, **2009**, 37, 1157-66	3.1	8
125	Outside the box--novel therapeutic strategies for glioblastoma. *Cancer Journal (Sudbury, Mass.)*, **2012**, 18, 51-8	2.2	8
124	Expansion and transduction of nonenriched human cord blood cells using HS-5 conditioned medium and FLT3-L. *Journal of Hematotherapy and Stem Cell Research*, **2000**, 9, 759-65		8
123	The frequency of multipotent CD133(+)CD45RA(-)CD34(+) hematopoietic stem cells is not increased in fetal liver compared with adult stem cell sources. *Experimental Hematology*, **2016**, 44, 502-7	3.1	8
122	Evidence for persistence of the SHIV reservoir early after MHC haploidentical hematopoietic stem cell transplantation. *Nature Communications*, **2018**, 9, 4438	17.4	8
121	Differential effects of HOXB4 and NUP98-HOXA10hd on hematopoietic repopulating cells in a nonhuman primate model. *Human Gene Therapy*, **2011**, 22, 1475-82	4.8	7
120	Ex vivo expansion and lentiviral transduction of Macaca nemestrina CD4+ T cells. *Journal of Medical Primatology*, **2009**, 38, 438-43	0.7	7

119	Highly efficient gene transfer into preterm CD34 hematopoietic progenitor cells. *American Journal of Obstetrics and Gynecology*, **2000**, 183, 732-7	6.4	7
118	Gene therapy and bone marrow transplantation. *Current Opinion in Oncology*, **1995**, 7, 107-14	4.2	7
117	Gene Transfer into Marrow Repopulating Cells: Comparison Between Amphotropic and Gibbon Ape Leukemia Virus Pseudotyped Retroviral Vectors in a Competitive Repopulation Assay in Baboons. *Blood*, **1997**, 90, 4638-4645	2.2	7
116	In-Vivo Gene Therapy with Foamy Virus Vectors. *Viruses*, **2019**, 11,	6.2	7
115	Overexpression of glutathione-S-transferase, MGSTII, confers resistance to busulfan and melphalan. *Cancer Investigation*, **2005**, 23, 19-25	2.1	7
114	The CD33 splice isoform lacking exon 2 as therapeutic target in human acute myeloid leukemia. *Leukemia*, **2020**, 34, 2479-2483	10.7	6
113	Fanconi anemia type C-deficient hematopoietic cells are resistant to TRAIL (TNF-related apoptosis-inducing ligand)-induced cleavage of pro-caspase-8. *Experimental Hematology*, **2004**, 32, 815-21	3.1	6
112	Gene Therapy for Fanconi Anemia in Seattle: Clinical Experience and Next Steps. *Blood*, **2016**, 128, 3510-3510	25	6
111	CAR T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies. *Lancet Haematology,the*, **2020**, 7, e690-e696	14.6	6
110	DNA Barcoding in Nonhuman Primates Reveals Important Limitations in Retrovirus Integration Site Analysis. *Molecular Therapy - Methods and Clinical Development*, **2020**, 17, 796-809	6.4	6
109	Safe and Effective Targeting and Gene Editing in Hematopoietic Stem Cells: Strategies for Accelerating Development. *Human Gene Therapy*, **2021**, 32, 31-42	4.8	6
108	Efficacy and Toxicity of CD19-Specific Chimeric Antigen Receptor T Cells Alone or in Combination with Ibrutinib for Relapsed and/or Refractory CLL. *Biology of Blood and Marrow Transplantation*, **2019**, 25, S9-S10	4.7	5
107	Gene therapy studies in a canine model of X-linked severe combined immunodeficiency. *Human Gene Therapy Clinical Development*, **2015**, 26, 50-6	3.2	5
106	Novel reporter systems for facile evaluation of I-SceI-mediated genome editing. *Nucleic Acids Research*, **2012**, 40, e14	20.1	5
105	Stem cell-derived CAR T cells traffic to HIV reservoirs in macaques. *JCI Insight*, **2021**, 6,	9.9	5
104	TRAILshort Protects against CD4 T Cell Death during Acute HIV Infection. *Journal of Immunology*, **2019**, 203, 718-724	5.3	4
103	Refining Current Scientific Priorities and Identifying New Scientific Gaps in HIV-Related Heart, Lung, Blood, and Sleep Research. *AIDS Research and Human Retroviruses*, **2017**, 33, 889-897	1.6	4
102	In vivo protection of activated Tyr22-dihydrofolate reductase gene-modified canine T lymphocytes from methotrexate. *Journal of Gene Medicine*, **2013**, 15, 233-41	3.5	4

101	Proliferation-linked apoptosis of adoptively transferred T cells after IL-15 administration in macaques. *PLoS ONE*, **2013**, 8, e56268	3.7	4
100	Mouse models in hematopoietic stem cell gene therapy and genome editing. *Biochemical Pharmacology*, **2020**, 174, 113692	6	4
99	Gene Transfer in Adeno-Associated Virus Seropositive Rhesus Macaques Following Rapamycin Treatment and Subcutaneous Delivery of AAV6, but Not Retargeted AAV6 Vectors. *Human Gene Therapy*, **2021**, 32, 96-112	4.8	4
98	Thresholds for post-rebound SHIV control after CCR5 gene-edited autologous hematopoietic cell transplantation. *ELife*, **2021**, 10,	8.9	4
97	Preparation and Gene Modification of Nonhuman Primate Hematopoietic Stem and Progenitor Cells. *Journal of Visualized Experiments*, **2019**,	1.6	3
96	The effect of imatinib on cytomegalovirus reactivation in hematopoietic cell transplantation. *Clinical Infectious Diseases*, **2009**, 49, e120-3	11.6	3
95	Induction of transgene-specific cytotoxic T lymphocyte responses after transplantation of gene-modified CD34+ cells despite nonablative immunosuppressive conditioning. *Human Gene Therapy*, **2008**, 19, 103-7	4.8	3
94	Long-Term Increase in Fetal Hemoglobin Expression in Nonhuman Primates Following Transplantation of Autologous Bcl11a Nuclease-Edited HSCs. *Blood*, **2015**, 126, 2035-2035	2.2	3
93	Safe and efficient hematopoietic stem cell transduction in nonhuman primates using HDAd5/35++ vectors.. *Molecular Therapy - Methods and Clinical Development*, **2022**, 24, 127-141	6.4	3
92	Single-dose MGTA-145/plerixafor leads to efficient mobilization and in vivo transduction of HSCs with thalassemia correction in mice. *Blood Advances*, **2021**, 5, 1239-1249	7.8	3
91	Efficient Enrichment of Gene-Modified Primary T Cells via CCR5-Targeted Integration of Mutant Dihydrofolate Reductase. *Molecular Therapy - Methods and Clinical Development*, **2018**, 9, 347-357	6.4	3
90	Radiation-induced glioblastoma multiforme in two adult baboons (Papio cynocephalus anubis). *Comparative Medicine*, **2004**, 54, 327-32	1.6	3
89	Autologous, Gene-Modified Hematopoietic Stem and Progenitor Cells Repopulate the Central Nervous System with Distinct Clonal Variants. *Stem Cell Reports*, **2019**, 13, 91-104	8	2
88	Envelope-Specific Adaptive Immunity following Transplantation of Hematopoietic Stem Cells Modified with VSV-G Lentivirus. *Molecular Therapy - Methods and Clinical Development*, **2020**, 19, 438-446	6.4	2
87	Sirolimus and tacrolimus binding proteins: double-edged swords for GVHD prophylaxis. *Blood*, **2003**, 102, 1562-1562	2.2	2
86	Relapsed or Refractory CLL after CD19-Specific CAR-T Therapy: Treatment Patterns and Clinical Outcomes. *Blood*, **2019**, 134, 4294-4294	2.2	2
85	Transmission of Chagas disease via blood transfusions in 2 immunosuppressed pigtailed macaques (Macaca nemestrina). *Comparative Medicine*, **2014**, 64, 63-7	1.6	2
84	Large Scale Analysis of Foamy Virus Vector Integration Sites in Human CD34+ Cells.. *Blood*, **2004**, 104, 496-496	2.2	2

83	Multiplex CRISPR/Cas9 genome editing in hematopoietic stem cells for fetal hemoglobin reinduction generates chromosomal translocations. *Molecular Therapy - Methods and Clinical Development*, **2021**, 23, 507-523	6.4	2
82	Sort-purification of human CD34+CD90+ cells reduces target cell population and improves lentiviral transduction for gene therapy		2
81	Devouring the Hematopoietic Stem Cell: Setting the Table for Marrow Cell Transplantation. *Molecular Therapy*, **2016**, 24, 1892-1894	11.7	2
80	CRISPR/Cas9 for the treatment of haematological diseases: a journey from bacteria to the bedside. *British Journal of Haematology*, **2021**, 192, 33-49	4.5	2
79	AMD3100 redosing fails to repeatedly mobilize hematopoietic stem cells in the nonhuman primate and humanized mouse. *Experimental Hematology*, **2021**, 93, 52-60.e1	3.1	2
78	Genome editing in large animal models. *Molecular Therapy*, **2021**, 29, 3140-3152	11.7	2
77	Synthetic introns enable splicing factor mutation-dependent targeting of cancer cells.. *Nature Biotechnology*, **2022**,	44.5	2
76	Expression of Herpes Simplex Virus ICP47 and Human Cytomegalovirus US11 Prevents Recognition of Transgene Products by CD8+ Cytotoxic T Lymphocytes. *Journal of Virology*, **2000**, 74, 4465-4473	6.6	2
75	Minimal conditioning in Fanconi anemia promotes multi-lineage marrow engraftment at 10-fold lower cell doses. *Journal of Gene Medicine*, **2018**, 20, e3050	3.5	1
74	No evidence of clonal dominance after transplant of HOXB4-expanded cord blood cells in a nonhuman primate model. *Experimental Hematology*, **2014**, 42, 497-504	3.1	1
73	Insights into leukemia-initiating cell frequency and self-renewal from a novel canine model of leukemia. *Experimental Hematology*, **2011**, 39, 124-32	3.1	1
72	All-trans retinoic acid facilitates oncoretrovirus-mediated transduction of hematopoietic repopulating stem cells. *Journal of Hematotherapy and Stem Cell Research*, **2001**, 10, 815-25		1
71	Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma. *Blood*, **2020**, 136, 1-2	2.2	1
70	CD45-targeted antibody-drug-conjugate successfully conditions for allogeneic hematopoietic stem cell transplantation.. *Blood*, **2022**,	2.2	1
69	Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. *Blood*, **2018**, 132, 1681-1681	2.2	1
68	From Bone Marrow to Mobilized Peripheral Blood Stem Cells: The Circuitous Path to Clinical Gene Therapy for Fanconi Anemia. *Blood*, **2018**, 132, 2208-2208	2.2	1
67	Multi-Copy Integration after HIV-Derived Lentivirus Vector Transduction of Murine Hematopoietic Stem Cells Does Not Promote Clonal Proliferation in Primary or Secondary Recipients.. *Blood*, **2004**, 104, 2105-2105	2.2	1
66	Development of Leukemia after HOXB4 Gene Transfer in the Canine Model.. *Blood*, **2006**, 108, 204-204	2.2	1

65	Effective Expansion and Engraftment Of Nonhuman Primate CD34+Hematopoietic Stem Cells After Co-Culture With The Small Molecule UM171. *Blood*, **2013**, 122, 1656-1656	2.2	1
64	Gene Editing of CCR5 in Hematopoietic Stem Cells in a Nonhuman Primate Model of HIV/AIDS. *Blood*, **2014**, 124, 4802-4802	2.2	1
63	Pgk-Mediated Expression of Common Gamma Chain Is More Effective Than EF1a for Therapeutic Immune Reconstitution of X-SCID Dogs after In Vivo Gene Therapy with Foamy Virus Vector. *Blood*, **2015**, 126, 262-262	2.2	1
62	Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL. *Blood*, **2021**, 138, 3872-3872	2.2	1
61	Persistent Control of SIV Infection in Rhesus Macaques By Expressing a Highly Potent SIV Decoy Receptor after In Vivo HSC Transduction. *Blood*, **2021**, 138, 1855-1855	2.2	1
60	NOD/SCID Repopulating Cells Contribute Only to Short-Term Repopulation in the Baboon.. *Blood*, **2005**, 106, 1711-1711	2.2	1
59	Safety Of a Gamma Globin Expressing Lentivirus Vector In a Non-Human Primate Model For Gene Therapy Of Sickle Cell Disease. *Blood*, **2013**, 122, 2896-2896	2.2	1
58	Rethinking the Regulatory Infrastructure for Human Gene Transfer Clinical Trials. *Molecular Therapy* , **2016**, 24, 1173-7	11.7	1
57	Gene Therapy for Canine SCID-X1 Using Cocal-Pseudotyped Lentiviral Vector. *Human Gene Therapy*, **2021**, 32, 113-127	4.8	1
56	Targeting the membrane-proximal C2-set domain of CD33 for improved CD33-directed immunotherapy. *Leukemia*, **2021**, 35, 2496-2507	10.7	1
55	Immune inactivation of anti-simian immunodeficiency virus chimeric antigen receptor T cells in rhesus macaques. *Molecular Therapy - Methods and Clinical Development*, **2021**, 22, 304-319	6.4	1
54	Hematopoietic recovery after transplantation is primarily derived from the stochastic contribution of hematopoietic stem cells		1
53	Efficient polymer nanoparticle-mediated delivery of gene editing reagents into human hematopoietic stem and progenitor cells.. *Molecular Therapy*, **2022**,	11.7	1
52	Isolation of a Highly Purified HSC-enriched CD34CD90CD45RA Cell Subset for Allogeneic Transplantation in the Nonhuman Primate Large-animal Model. *Transplantation Direct*, **2020**, 6, e579	2.3	0
51	Intracellular RNase activity dampens zinc finger nuclease-mediated gene editing in hematopoietic stem and progenitor cells.. *Molecular Therapy - Methods and Clinical Development*, **2022**, 24, 30-39	6.4	0
50	CD133+ CD34+ HSPCs Are Not Significantly Increased in Fetal Liver Compared to Adult or Umbilical Cord HSPCs. *Blood*, **2015**, 126, 2369-2369	2.2	0
49	Efficient Nanoparticle-Mediated Delivery of Gene Editing Reagents into Human Hematopoietic Stem and Progenitor Cells. *Blood*, **2021**, 138, 2933-2933	2.2	
48	Myeloid-Biased HSC Require Semaphorin4a from the Bone Marrow Niche for Self-Renewal Under Stress and Life-Long Persistence. *Blood*, **2021**, 138, 3283-3283	2.2	

47	High-Density Clonal Analysis Reveals Highly Active Contribution of Multipotent Hematopoietic Stem Cells during Early Phases of Hematopoietic Recovery after Transplantation. *Blood*, **2021**, 138, 3258-3258	2.2
46	Oncoretroviral and Lentiviral Transduction of Donor T Cells to Facilitate Engraftment of Dog Leukocyte Antigen (DLA)-Haploidentical T-Cell-Depleted Marrow.. *Blood*, **2004**, 104, 1751-1751	2.2
45	Direct Intramarrow Injection of CD34+ Cells May Improve Long-Term Engraftment in Nonhuman Primates.. *Blood*, **2004**, 104, 2103-2103	2.2
44	A Non-Human Primate Model for Lentivirus-Mediated Anti-HIV RNAi Strategies.. *Blood*, **2004**, 104, 3103-3103	2.2
43	HOXB4-Mediated Immortalization of Murine Hematopoietic Stem/Progenitor Cells.. *Blood*, **2004**, 104, 4149-4149	2.2
42	Molecular Characterization of Stem Cell Populations and Specific Clone Tracking of Retrovirally-Marked Chemoprotected Stem Cells before and after Dose-Escalating Chemotherapy.. *Blood*, **2004**, 104, 291-291	2.2
41	Reducing Stem Cell Loss and Ex Vivo Differentiation during Lentivirus Gene Transfer to Murine Stem Cells - an Ultra-Short Transduction Protocol.. *Blood*, **2004**, 104, 2113-2113	2.2
40	A Comparison of Mesenchymal Cells from Different Tissues To Suppress T-Cell Activation.. *Blood*, **2005**, 106, 4323-4323	2.2
39	Genomic Mapping of Retrovirus Integration Profiles after In Vivo Selection of Chemo-Protected Stem Cells in the Clinically Relevant Canine Model.. *Blood*, **2005**, 106, 1293-1293	2.2
38	A Non-Human Primate Model To Study Anti-HIV Gene Therapy Strategies.. *Blood*, **2005**, 106, 3046-3046	2.2
37	Estimating the Replication Rate of Hematopoietic Stem Cells in Non-Human Primates: A Test of Hayflick Hypothesis.. *Blood*, **2005**, 106, 1710-1710	2.2
36	Differential Effects of HOXB4 Overexpression on Short and Long-Term Repopulating Cells in Nonhuman Primates.. *Blood*, **2005**, 106, 33-33	2.2
35	Sustained Stable Engraftment of MGMT Gene-Modified Long-Term Repopulating Cells in Primary and Secondary Canine Recipients.. *Blood*, **2006**, 108, 202-202	2.2
34	Unique Integration Profiles of Gammaretrovirus, Lentivirus, and Foamy Virus Transduced Dog Long-Term Repopulating Cells.. *Blood*, **2006**, 108, 3252-3252	2.2
33	MGMT (P140K) Allows for Efficient and Sustained In Vivo Selection in Non-Human Primates.. *Blood*, **2006**, 108, 3270-3270	2.2
32	Transduction of Macaque Hematopoietic Repopulating Cells with Lenti and Foamy Retroviral Vectors with MGMT Selection Cassettes To Evaluate AIDS Gene Therapy Strategies.. *Blood*, **2006**, 108, 3273-3273	2.2
31	Change of Treatment for Control of Chronic Graft-Versus-Host Disease (cGVHD) as a Time-Dependent Covariate for Nonrelapse Mortality and Survival.. *Blood*, **2007**, 110, 833-833	2.2
30	Modeling and Understanding the Biology of Transplant-Mediated HIV Cure in a Non-Human Primate Model. *Blood*, **2017**, 130, 694-694	2.2

29	Non-Genotoxic Conditioning Efficiently Depletes Host Hematopoietic Stem Cells and Facilitates Robust Multi-Lineage Engraftment in a Mouse Model of Fanconi Anemia. *Blood*, **2018**, 132, 2041-2041	2.2
28	Persistence of CRISPR/Cas9-Edited Hematopoietic Stem and Progenitor Cells and Reactivation of Fetal Hemoglobin in Nonhuman Primates. *Blood*, **2018**, 132, 806-806	2.2
27	Multivariable Modeling of Disease and Treatment Characteristics of Adults with B-ALL in MRD-Negative CR after CD19 CAR-T Cells Identifies Factors Impacting Disease-Free Survival. *Blood*, **2018**, 132, 281-281	2.2
26	Engineering Resistance to CD33-Targeted Immunotherapy in Normal Hematopoiesis By CRISPR/Cas9-Deletion of CD33 Exon 2. *Blood*, **2018**, 132, 2200-2200	2.2
25	CRISPR/Cas9-Mediated Protection of Normal Hematopoiesis Combined with the CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody AMG330 for Improved AML Therapy. *Blood*, **2019**, 134, 4427-4427	2.2
24	Fully Closed, Large-Scale, and Clinical Grade Cell Sorting of Hematopoietic Stem Cell (HSC)-Enriched CD90+ Cells for Transplantation and Gene Therapy. *Blood*, **2019**, 134, 3246-3246	2.2
23	Pyrimido-Indole Derivatives Are Novel Agonists of Human Cord Blood Hematopoietic Stem Cell Self-Renewal. *Blood*, **2014**, 124, 650-650	2.2
22	Novel Integrated Autologous Hematopoietic Stem Cell Tracking in Nonhuman Primates Reveals Successive Pattern of Multi-Lineage Reconstitution after Total Body Irradiation. *Blood*, **2014**, 124, 2910-2910	2.2
21	Robust Therapeutic Expression of the Common Gamma Chain with the Human Pgk Promoter Using Foamy Virus in Vivo Gene Therapy in a Canine Model of Severe Combined Immunodeficiency. *Blood*, **2014**, 124, 4794-4794	2.2
20	A Point-of-Care Platform for Hematopoietic Stem Cell Gene Therapy. *Blood*, **2015**, 126, 4416-4416	2.2
19	In Vivo Selection Unmasks a Dormant Pool of Repopulating Hematopoietic Clones. *Blood*, **2015**, 126, 242-242	2.2
18	Maintenance of Leukocyte Telomere Length after Transplant and Chemoselection in Macaques with Polyclonal Gene Modified Cell Engraftment. *Blood*, **2015**, 126, 3236-3236	2.2
17	Conserved Lineage Development in Human and Nonhuman Primate Hematopoiesis. *Blood*, **2016**, 128, 2646-2646	2.2
16	Rapid Expansion of Gene-Marked Lymphocytes in X-SCID Dogs after AMD3100+G-CSF-Based Hematopoietic Stem/Progenitor Cell Mobilization and Intravenous Injection of a Common □Chain Expressing Foamy Viral Vector. *Blood*, **2016**, 128, 1348-1348	2.2
15	Comprehensive Integration Site Analysis of Human Immunodeficiency Virus during In Vivo Infections Reveals Genomic Regions of Enrichment and Clonal Expansion. *Blood*, **2016**, 128, 2518-2518	2.2
14	Dual-Method Clone Tracking in Nonhuman Primates Confirms Long-Term Hematopoietic Reconstitution Initiated By Early Engrafting Clones. *Blood*, **2016**, 128, 1475-1475	2.2
13	Identification and Characterization of a Distinct, Evolutionarily Conserved HSC Phenotype Associated with and Predicting Multi-Lineage Engraftment. *Blood*, **2016**, 128, 1153-1153	2.2
12	Efficient Gene Marking with a Clinical Gammaretrovirus Vector Expressing MGMTP140K in Baboons and Macaques. *Blood*, **2008**, 112, 3535-3535	2.2

11	Correction of Fanconi Anemia Group A in Primary Human and Murine Hematopoietic Progenitors with a Clinical Lentiviral Vector. *Blood*, **2008**, 112, 2357-2357	2.2
10	Efficient MGMTP140K-Mediated In Vivo Selection and Chemoprotection of Long-Term Repopulating Cells in Nonhuman Primates Following Reduced Intensity Conditioning.. *Blood*, **2009**, 114, 3572-3572	2.2
9	Towards Defining An Optimal Conditioning Regimen for Stem Cell Gene Therapy In Fanconi Anemia.. *Blood*, **2010**, 116, 1478-1478	2.2
8	A Retrospective Comparison of Tacrolimus Vs. Cyclosporine for Immunosuppression After Allogeneic Hematopoietic Cell Transplantation with G-CSF-Mobilized Blood Cells. *Blood*, **2010**, 116, 2319-2319	2.2
7	Integration-Mediated Activation of PRDM16 and HMGA2 in Multiple Clones without Adverse Hematopoietic Consequences Following Transplant of Autologous MGMTP140K Gene-Modified CD34+ Cells. *Blood*, **2011**, 118, 2053-2053	2.2
6	Drug Resistance Gene Therapy to Augment Allogeneic Transplantation for the Treatment of Leukemia Following Relapse. *Blood*, **2011**, 118, 2050-2050	2.2
5	In Vivo Selection and Long-Term Engraftment Of Hematopoietic Stem Cells Generated Via Vascular Niche Induction Of Nonhuman Primate Induced Pluripotent Stem Cells. *Blood*, **2013**, 122, 466-466	2.2
4	Modulated Cyclophosphamide-Based In Vivo T-Cell Depletion Promotes Engraftment With Minimal Gvhd and Low Toxicity In Fanconi Anemia Patients. *Blood*, **2013**, 122, 4561-4561	2.2
3	Genetic Manipulation of Hematopoietic Stem Cells **2016**, 78-99	
2	The evolution of viral integration site analysis. *Blood*, **2020**, 135, 1192-1193	2.2
1	Genetic Manipulation of Hematopoietic Stem Cells116-128	